Acquisition of biospecimens for studying skin diseases
Official title: Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
Run by National Institutes of Health Clinical Center (CC) · NCT02471352 · Data updated 2026-11-12
This study is collecting samples from people with skin diseases, those at risk, and healthy volunteers to see how skin conditions affect quality of life and to learn more about their causes and treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Day to 100 Years |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | June 19, 2015 |
| Main results expected | January 31, 2035 |
| Study ends | January 31, 2035 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT02471352 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 2 and older with dermatologic conditions, those at risk for developing such conditions, family members of affected individuals, and healthy volunteers.
✕Probably not a fit
Patients with conditions that may pose undue risk or those unable to comply with the study protocol may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect biological samples from individuals with dermatologic conditions, those at risk for such conditions, and healthy volunteers. Participants will undergo a medical history review, physical exams, and surveys to assess the impact of skin diseases on their quality of life. The collected specimens, including blood, stool, and nail samples, will be used for exploratory studies to understand the causes and potential treatments for various skin diseases. The study anticipates enrolling approximately 700 participants over a 10-year period.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of skin diseases and improved treatment options for patients.
How similar studies have gone: Other studies focusing on biospecimen collection for dermatologic conditions have shown promise, indicating that this approach is supported by prior research.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Eligible participants must: * Have a dermatologic condition, as determined by the PI or AIs, OR --be at risk for developing a dermatologic condition, as determined by the PI or AIs, OR * be a family member of a person with a dermatologic condition OR * be a healthy volunteer, as defined as a person with no known significant health problems. * Be willing to provide biospecimens for research and clinical studies, and for storage to be used for future research. * Subjects of age greater than 0 years old (including only viable neonates) are eligible. EXCLUSION CRITERIA: * Presence of conditions that, in the judgment of the investigator, may put the subject at undue risk or make them unsuitable for participation in the study. * Inability to comply with the requirements of the protocol.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Heidi H Kong, M.D. — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Study coordinator: Heidi H Kong, M.D.
- Email: NIAMSderm@nih.gov
- Phone: (301) 827-2460
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pembrolizumab treatment for Japanese children with solid tumors or lymphomas and Japanese adults with Merkel cell carcinoma
This study will try pembrolizumab in Japanese children with solid tumors or lymphomas and in Japanese adults with Merkel cell carcinoma to learn about safety, how the drug moves through the body, and whether tumors shrink.
-
Collection of human tissue samples for biomedical research
This study is collecting blood, urine, and saliva samples from healthy volunteers and people with certain conditions to help researchers learn more about diseases and develop new treatments.
-
Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma
This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors
This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.
-
Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors
This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.